Recruiting PHASE1 INTERVENTIONAL 1-arm NCT04848064

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas

Sponsor: John Reneau

Conditions Recurrent Adult T-Cell Leukemia/Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Refractory Adult T-Cell Leukemia/Lymphoma Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions Cyclophosphamide Fludarabine Mogamulizumab Natural Killer Cell Therapy Quality-of-Life Assessment Questionnaire Administration

Updated 11 times since 2021 Last updated: Feb 6, 2026 Started: May 6, 2022 Primary completion: Oct 30, 2026 Completion: Jan 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Recurrent Adult T-Cell Leukemia/Lymphoma and Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, this trial is actively recruiting participants. The trial is conducted by John Reneau and has accumulated 11 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

11 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1
Jul 2025 — Feb 2026 [monthly]

Recruiting PHASE1
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1
Mar 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE1

▶ Show 6 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Dec 2022 — Feb 2024 [monthly]

Recruiting PHASE1
Nov 2021 — Dec 2022 [monthly]

Recruiting PHASE1
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
May 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

John Reneau

Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States